Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Emerging STAR in Molecular Biology, Synthetic Virology and Genomics: Clodagh C. O’Shea: ChromEMT – Visualizing 3D chromatin structure

Curator: Aviva Lev-Ari, PhD, RN

On 8/28/2017, I attend and covered in REAL TIME the CHI’s 5th Immune Oncology Summit – Oncolytic Virus Immunotherapy, August 28-29, 2017 Sheraton Boston Hotel | Boston, MA

https://pharmaceuticalintelligence.com/2017/08/28/live-828-chis-5th-immune-oncology-summit-oncolytic-virus-immunotherapy-august-28-29-2017-sheraton-boston-hotel-boston-ma/

I covered in REAL TIME this event and Clodagh C. O’Shea talk at the conference.

On that evening, I e-mailed my team that

“I believe that Clodagh C. O’Shea will get the Nobel Prizebefore CRISPR

11:00 Synthetic Virology: Modular Assembly of Designer Viruses for Cancer Therapy

Clodagh O’Shea, Ph.D., Howard Hughes Medical Institute Faculty Scholar; Associate Professor, William Scandling Developmental Chair, Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies

Design is the ultimate test of understanding. For oncolytic therapies to achieve their potential, we need a deep mechanistic understanding of virus and tumor biology together with the ability to confer new properties.

To achieve this, we have developed

• combinatorial modular genome assembly (ADsembly) platforms,
• orthogonal capsid functionalization technologies (RapAd) and
• replication assays that have enabled the rational design, directed evolution, systematic assembly and screening of powerful new vectors and oncolytic viruses.

Clodagh O’Shea’s Talk In Real Time:

• Future Cancer therapies to be sophisticated as Cancer is
• Targer suppresor pathways (Rb/p53)
• OV are safe their efficacy ishas been limited
• MOA: Specify Oncolytic Viral Replication in Tumor cells Attenuate – lack of potency
• SOLUTIONS: Assembly: Assmble personalized V Tx fro libraries of functional parts
• Adenovirus – natural & clinical advantages
• Strategy: Technology for Assmbling Novel Adenovirus Genomes using Modular Genomic Parts
• E1 module: Inactives Rb & p53
• core module:
• E3 Module Immune Evasion Tissue targeting
• E4 Module Activates E2F (transcription factor TDP1/2), PI3K
• Adenovirus promoters for Cellular viral replication — Tumor Selective Replication: Novel Viruses Selective Replicate in RB/p16
• Engineering Viruses to overcome tumor heterogeneity
• Target multiple & Specific Tumor Cel Receptors – RapAd Technology allows Re-targeting anti Rapamycin – induced targeting of adenovirus
• Virus Genome: FKBP-fusion FRB-Fiber
• Engineer Adenovirus Caspids that prevent Liver uptake and Sequestration – Natural Ad5 Therapies 
• Solution: AdSyn335 Lead candidat AdSyn335 Viruses targeting multiple cells
• Engineering Mutations that enhanced potency
• Novel Vector: Homes and targets
• Genetically engineered PDX1 – for Pancreatic Cancer Stroma: Early and Late Stage

 

Scientist’s Profile: Clodagh C. O’Shea

http://www.salk.edu/scientist/clodagh-oshea/

 

EDUCATION

BS, Biochemistry and Microbiology, University College Cork, Ireland
PhD, Imperial College London/Imperial Cancer Research Fund, U.K.
Postdoctoral Fellow, UCSF Comprehensive Cancer Center, San Francisco, U.S.A

VIDEOS

http://www.salk.edu/scientist/clodagh-oshea/videos/

O’Shea Lab @Salk

http://oshea.salk.edu/

AWARDS & HONORS

• 2016 Howard Hughes Medical Institute Faculty Scholar
• 2014 W. M. Keck Medical Research Program Award
• 2014 Rose Hills Fellow
• 2011Science/NSF International Science & Visualization Challenge, People’s Choice
• 2011 Anna Fuller Award for Cancer Research
• 2010, 2011, 2012 Kavli Frontiers Fellow, National Academy of Sciences
• 2009 Sontag Distinguished Scientist Award
• 2009 American Cancer Society Research Scholar Award
• 2008 ACGT Young Investigator Award for Cancer Gene Therapy
• 2008 Arnold and Mabel Beckman Young Investigator Award
• 2008 William Scandling Assistant Professor, Developmental Chair
• 2007 Emerald Foundation Schola

READ 

Clodagh C. O’Shea: ChromEMT: Visualizing 3D chromatin structure and compaction in interphase and mitotic cells | Science

http://science.sciencemag.org/content/357/6349/eaag0025

and 

https://www.readbyqxmd.com/keyword/93030

 

Clodagh C. O’Shea

In Press

Jul 27, 2017 – Salk scientists solve longstanding biological mystery of DNA organization

Sep 22, 2016 – Clodagh O’Shea named HHMI Faculty Scholar for groundbreaking work in designing synthetic viruses to destroy cancer

Oct 05, 2015 – Clodagh O’Shea awarded $3 million to unlock the “black box” of the nucleus

Aug 27, 2015 – The DNA damage response goes viral: a way in for new cancer treatments

Apr 12, 2013 – Salk Institute promotes three top scientists

Oct 16, 2012 – Cold viruses point the way to new cancer therapies

Aug 25, 2010 – Use the common cold virus to target and disrupt cancer cells?

Oct 22, 2009 – Salk scientist receives The Sontag Foundation’s Distinguished Scientist Award

May 15, 2008 – Salk scientist wins 2008 Beckman Young Investigator Award

Mar 24, 2008 – Salk scientist wins 2007 Young Investigator’s Award in Gene Therapy for Cancer